Authors
Latest:
Prepare Now to Avoid the BurnThe sponsors of clinical trials Sunshine Act legislation to improve their physician payment processes, educate the public on the complexity of clinical research and development, and help patients make informed opinions about physicians - bringing true transparency to the financial aspects of discovering new medical treatments.
Latest:
DTC: European StyleIn 1996, Sandoz (now Novartis) decided to brave new waters to create consumer demand for the antifungal Lamisil (terbinafine) in the United Kingdom. But with European law forbidding pharma companies to conduct brand-name advertising, Sandoz needed to find another way to encourage patients to talk with their doctors about onychomycosis and its treatment options. So the company re-named the condition the more consumer-friendly "fungal infection" and took out newspaper ads asking readers to call or write to "Step Wise" for a free brochure on foot care.
Latest:
Establishing a Data Ecosystem Using Automation to Optimize Regulatory-Compliant Clinical TrialsWebinar Date/Time: Thursday, May 23, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
Latest:
Specialty Pharma Is on the MoveOne of the fastest growing segments in the industry, specialty pharmaceuticals are proving tough to track for most companies-creating critical gaps in the supply chain view that can distort strategic planning and impact competitive advantage.
Latest:
Specialty Therapies Lose Special StatusFuture savings from specialty pharmacies will come at pharma companies' expense.
Latest:
The Ecology of Sampling: A Call to ActionThe pharmaceutical industry distributes more than $22 billion worth of medication samples in the US alone. It's time to revisit the issue of waste inherent in this marketing strategy.
Latest:
Marketing to Professionals: Doctor-Patient CommunicationInstead of leaving the doctor's office well informed, the patient often leaves without enough comprehensible information to comply with the prescribed treatment.
Latest:
Survival/Success in the Age of Too Much InformationTo get their messages out in this age of polarisation and "too much information", marketers need to shout louder, have a more dramatic point of view and gather a league of similar advocates to succeed. Al Topin sees the solution in common sense and courage.
Latest:
Minimizing Mass Tort ExposureIn today's legal climate, pharmaceutical companies are prime targets for litigation in both state and federal courts. Because they are engaged in product research and development and related complex business practices spread across many jurisdictions and because the public perceives the industry as having deep pockets, executives must be prepared for-and frankly must expect to face-the challenges of major multijurisdictional litigation.
Latest:
This Is Going to HurtThe President and Congress are sounding the alarm on the need for healthcare reform. There are several near-certainties for which pharmaceutical and biotechnology companies must be prepared as they develop forecasts and for the next five or six years.
Latest:
Executive Prophesies Vision for the FutureFor the pharma industry, the year 2002 brought unprecedented competition, pricing pressures, public scrutiny, and ever-increasing regulation, all exacerbated by a weak economy. (See "Defining Events," pages 50-56.) Although a few companies forged new partnerships and produced life-saving treatments, many more struggled to meet the industry's challenges. And no road map exists to guide them through today's continuing market pressures or to help them anticipate tomorrow's challenges.
Latest:
Patient Data Come of AgeContrary to popular belief, physicians still can't retrieve the full medical history of every patient who walks into their offices. Nor can they zap prescriptions through a clearinghouse that shows whether patients are eligible for coverage and reviews all medications they are taking to forestall drug?drug interactions.
Latest:
Inside the Doughnut HoleAn answer to your question: What does the Part D coverage gap do to drug sales?
Latest:
Managing the InnovatorInnovative products, and the research and development teams that produce them, are pharma's life blood. So it's no surprise that, according to PE's 2003 Top 50 Pharma, the largest 20 pharma companies alone spent $45.5 billion on R&D.
Latest:
The Virtues of Virtual TrainingAs the popularity of online training grows, many pharma companies are likely to implement learning management systems (LMS) that can manage the reams of data generated by training divisions in a regulated environment.
Latest:
Want to Be in a Health Plan? Think Like OnePharmacoactuarial analysis helps drug companies communicate value to health plans
Latest:
The Hispanic FactorWhat Big Pharma needs to learn-and value-about this rapidly growing US demographic
Latest:
Safe and Effective, Really?To decide on a course of treatment, patients need to be told the truth straight up
Latest:
Staying Ahead of the CurveSignificant and dramatic healthcare policy changes are likely to follow after Barack Obama takes the oath of office and the expanded Democratic congressional majority settles in. But what does the electoral outcome mean for healthcare companies and the industry as a whole?
Latest:
Data Vigilance and Validation: Lessons Learned, Future Hopes for Real-World DataBiopharma experts at the forefront of applying real-world data and real-world evidence across the product life cycle converge to discuss the lingering challenges in fully realizing the vast potential of these insights to transform the value equation.
Latest:
Rethinking the Sponsor-Investigator RelationshipWhen it comes to working with clinical research sites, pharmaceutical companies should take a page out of the automakers' playbook
